Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress

被引:37
|
作者
Masciarelli, S. [1 ]
Capuano, E. [1 ]
Ottone, T. [2 ]
Divona, M. [2 ]
De Panfilis, S. [3 ]
Banella, C. [4 ]
Noguera, N. I. [2 ,4 ]
Picardi, A. [5 ]
Fontemaggi, G.
Blandino, G. [6 ]
Lo-Coco, F. [2 ,4 ,6 ]
Fazi, F. [1 ]
机构
[1] Sapienza Univ Rome, Dept Anat Histol Forens & Orthoped Sci, Sect Histol & Med Embryol, Via A Scarpa 14-16, I-00161 Rome, Italy
[2] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy
[3] Ist Italiano Tecnol, Ctr Life Nanosci, Rome, Italy
[4] Santa Lucia Fdn, Lab Neurooncohematol Unit, Rome, Italy
[5] Univ Roma Tor Vergata, Dept Biomed & Prevent, Stem Cell Transplant Unit, Rome Transplant Network, Rome, Italy
[6] Regina Elena Inst Canc Res, Oncogen & Epigenet Unit, Rome, Italy
关键词
UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS; SELECTIVE-INHIBITION; RAR-ALPHA; IN-VITRO; DEGRADATION; ACTIVATION; MECHANISMS; TRANSLATION;
D O I
10.1038/leu.2017.231
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Retinoic acid (RA) in association with chemotherapy or with arsenic trioxide (ATO) results in high cure rates of acute promyelocytic leukemia (APL). We show that RA-induced differentiation of human leukemic cell lines and primary blasts dramatically increases their sensitivity to endoplasmic reticulum (ER) stress-inducing drugs at doses that are not toxic in the absence of RA. In addition, we demonstrate that the PERK pathway, triggered in response to ER stress, has a major protective role. Moreover, low amounts of pharmacologically induced ER stress are sufficient to strongly increase ATO toxicity. Indeed, in the presence of ER stress, ATO efficiently induced apoptosis in RA-sensitive and RA-resistant APL cell lines, at doses ineffective in the absence of ER stress. Our findings identify the ER stress-related pathways as potential targets in the search for novel therapeutic strategies in AML.
引用
收藏
页码:285 / 294
页数:10
相关论文
共 50 条
  • [31] Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia
    Lin, CP
    Huang, MJ
    Chang, IY
    Lin, WY
    Sheu, YT
    LEUKEMIA & LYMPHOMA, 2000, 38 (1-2) : 195 - +
  • [32] Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo.
    Jing, Y
    Wang, R
    Xia, L
    Chen, GQ
    Chen, Z
    Miller, W
    Waxman, S
    BLOOD, 1999, 94 (10) : 505A - 505A
  • [33] Arsenic trioxide in treatment of acute promyelocytic leukemia
    Ghavamzadeh, A
    Alimoghddam, K
    Aghdami, N
    Rastegarpanah, M
    Hosseini, R
    Tavassoli, P
    Jahani, M
    Khodabandeh, A
    Babordi, E
    Irvani, M
    Bahar, B
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 393 - 394
  • [34] Role of Arsenic Trioxide in Acute Promyelocytic Leukemia
    Iland, Harry J.
    Seymour, John F.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2013, 14 (02) : 170 - 184
  • [35] Treatment of acute promyelocytic leukemia with arsenic trioxide
    Tamm, I
    Paternostro, G
    Zapata, JM
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (13): : 1043 - 1043
  • [36] Arsenic trioxide: Acute promyelocytic leukemia and beyond
    Bachleitner-Hofmann, T
    Kees, M
    Gisslinger, H
    LEUKEMIA & LYMPHOMA, 2002, 43 (08) : 1535 - 1540
  • [37] Role of Arsenic Trioxide in Acute Promyelocytic Leukemia
    Harry J. Iland
    John F. Seymour
    Current Treatment Options in Oncology, 2013, 14 : 170 - 184
  • [38] Arsenic trioxide for the treatment of acute promyelocytic leukemia
    Lam, MSH
    Ignoffo, RJ
    CANCER PRACTICE, 2001, 9 (03) : 155 - 157
  • [39] Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all-trans retinoic acid and arsenic trioxide
    Habibi, Maryam
    Manouchehri Ardekani, Reza
    Motedayyen, Hossein
    CLINICAL CASE REPORTS, 2021, 9 (04): : 2192 - 2195
  • [40] Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia
    Zhao, WL
    Wang, HL
    Wang, XF
    Wu, P
    Guo, WM
    Qu, B
    Shen, ZX
    Wang, ZY
    THROMBOSIS RESEARCH, 2001, 102 (03) : 197 - 204